Hepatic uptake of technetium-99m HM-PAO in a fetus.
The normal biodistribution of technetium-99m HM-PAO ([99mTc]HM-PAO) includes significant uptake in the brain, liver, and kidneys. A pregnant patient studied with [99mTc] HM-PAO to confirm brain death provided an opportunity to examine the transplacental distribution of this radio-pharmaceutical in the unborn fetus. Uptake in the fetus after transplacental delivery is almost exclusively hepatic with a small amount of biliary excretion.
Maguire
C
C
Department of Nuclear Medicine, Victoria Hospital, London, Ontario, Canada.
Florence
S
S
Powe
J E
JE
Zabel
P L
PL
Driedger
A A
AA
D000328:Adult; D001926:Brain Death / Q000000981:diagnostic imaging*; D005260:Female; D005333:Fetus / Q000378:metabolism*; D006801:Humans; D008099:Liver / Q000378:metabolism*; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D010091:Oximes / Q000493:pharmacokinetics; D011247:Pregnancy; D011248:Pregnancy Complications / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019690:Technetium Tc 99m Exametazime
D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime